|
Press Releases |
|
 |
|
Friday, August 30, 2024 |
|
华领医药公布2024年中期业绩 |
华领医药(“公司”,香港联交所股份代号:2552)宣布公司及其附属公司截至2024年6月30日止,6个月(“报告期”)未经审核的综合业绩,以及公司上半年业务进展和未来业务展望。 more info >> |
|
Friday, August 25, 2023 |
|
华领医药公布2023年中期业绩 |
-- 全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(商品名:华堂宁®)于2022年9月在中国获批上市。 more info >> |
|
華領醫藥公佈2023年中期業績 |
-- 全球首創新藥葡萄糖激酶激活劑(GKA)多格列艾汀(商品名:華堂寧®)於2022年9月在中國獲批上市。 more info >> |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
华领医药全球首创新药葡萄糖激酶激活剂华堂宁(R)获批上市 有望拓展中国2型糖尿病治疗新格局 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,公司研发的全球首创(first-in-class)新药葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片,dorzagliatin,HMS5552)已于10月8日获得中国国家药品监督管理局(NMPA)的上市批准。 more info >> |
|
華領醫藥全球首創新藥葡萄糖激酶激活劑華堂寧(R)獲批上市 有望拓展中國2型糖尿病治療新格局 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,公司研發的全球首創(first-in-class)新藥葡萄糖激酶激活劑(GKA)華堂寧®(多格列艾汀片,dorzagliatin,HMS5552)已於10月8日獲得中國國家藥品監督管理局(NMPA)的上市批准。 more info >> |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
Tuesday, June 7, 2022 |
|
華領醫藥在2022ADA科學年會公佈多格列艾汀能夠明顯改善2型糖尿病患者和GCK-MODY患者的胰島素早相分泌和葡萄糖敏感性 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,在第82屆美國糖尿病協會(ADA)科學年會上,公司展示了其全球首創新藥葡萄糖激酶啟動劑(GKA)多格列艾汀(dorzagliatin)的多項臨床研究成果。 more info >> |
|
华领医药在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY患者的胰岛素早相分泌和葡萄糖敏感性 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,在第82届美国糖尿病协会(ADA)科学年会上,公司展示了其全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的多项临床研究成果。 more info >> |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 7, 2025 03:06 HKT/SGT
|
|
|
2024年華泰證券營收創新高 累計分紅46.94億元
Apr 6, 2025 22:30 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Apr 6, 2025 20:30 HKT/SGT
|
|
|
《周遊記3》開播 背後「隱藏玩家」巨星傳奇再造頂流綜藝IP
Apr 6, 2025 19:45 HKT/SGT
|
|
|
雲康集團2024年醫聯體共建業務及特檢項目收益佔比持續增長
Apr 6, 2025 18:27 HKT/SGT
|
|
|
Smart Lighting Expo and Spring Lighting Fair open today
Apr 6, 2025 16:55 HKT/SGT
|
|
|
ForexRova Debuts at International Forex Conference, Promises Smarter Gold Trading Solutions
Apr 5, 2025 19:00: JST
|
|
|
ForexRova Debuts at International Forex Conference, Promises Smarter Gold Trading Solutions
Apr 5, 2025 18:00 HKT/SGT
|
|
|
Connect Marketplace Hong Kong 2025 Concludes, Successfully Ushering in a New Era for MICE in the City
Apr 4, 2025 0:00 JST
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 4, 2025 22:48 HKT/SGT
|
|
|
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 4, 2025 22:08 HKT/SGT
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 4, 2025 21:15 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 4, 2025 20:50 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 4, 2025 20:40 HKT/SGT
|
|
|
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 4, 2025 15:56 JST
|
|
|
|
More News >> |
|
|
|
|
|